TimesSquare Capital Management LLC Boosts Stock Position in Vericel Co. (NASDAQ:VCEL)

TimesSquare Capital Management LLC raised its stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 7.1% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 632,160 shares of the biotechnology company's stock after purchasing an additional 42,015 shares during the period. TimesSquare Capital Management LLC owned 1.28% of Vericel worth $34,712,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. FMR LLC boosted its stake in shares of Vericel by 1.0% in the third quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company's stock worth $100,251,000 after acquiring an additional 22,461 shares during the period. Conestoga Capital Advisors LLC boosted its stake in shares of Vericel by 1.7% in the third quarter. Conestoga Capital Advisors LLC now owns 2,075,730 shares of the biotechnology company's stock worth $87,700,000 after acquiring an additional 34,360 shares during the period. Congress Asset Management Co. boosted its stake in shares of Vericel by 12.6% in the fourth quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company's stock worth $79,847,000 after acquiring an additional 162,419 shares during the period. Geode Capital Management LLC boosted its stake in Vericel by 0.8% during the third quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company's stock valued at $48,768,000 after buying an additional 9,613 shares during the last quarter. Finally, Geneva Capital Management LLC boosted its stake in Vericel by 61.4% during the third quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company's stock valued at $46,660,000 after buying an additional 420,078 shares during the last quarter.

Insider Buying and Selling

In related news, insider Jonathan Mark Hopper sold 10,000 shares of the company's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $58.72, for a total value of $587,200.00. Following the completion of the transaction, the insider now owns 58,371 shares of the company's stock, valued at approximately $3,427,545.12. This represents a 14.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now directly owns 26,595 shares of the company's stock, valued at $1,662,187.50. The trade was a 8.59 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,100 shares of company stock valued at $1,206,072. 5.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on VCEL. BTIG Research upped their price objective on Vericel from $56.00 to $66.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. Stephens reissued an "overweight" rating and issued a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. HC Wainwright reissued a "buy" rating and issued a $60.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. Canaccord Genuity Group increased their target price on Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Finally, Truist Financial boosted their target price on Vericel from $61.00 to $67.00 and gave the stock a "buy" rating in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Vericel has an average rating of "Moderate Buy" and a consensus target price of $63.14.

Vericel Stock Down 4.3 %

Shares of VCEL stock traded down $2.31 on Friday, hitting $52.00. The company had a trading volume of 414,572 shares, compared to its average volume of 321,010. The firm has a market cap of $2.57 billion, a P/E ratio of 866.81 and a beta of 1.72. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00. The company has a 50-day moving average price of $57.64 and a 200-day moving average price of $51.58.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.